You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

MultiTAA Specific T cells

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Houston (MultiTAA-specific T cells)

Recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndrome
  • MultiTAA-specific T cells
  • Houston, Texas
  • +1 more
May 31, 2022

Leukemia, Lymphoblastic (Acute) Trial in Houston (MultiTAA-specific T cells)

Active, not recruiting
  • Leukemia, Lymphoblastic (Acute)
  • MultiTAA-specific T cells
  • Houston, Texas
  • +1 more
Aug 6, 2021

Pancreatic Cancer Trial in Houston (multiTAA specific T cells)

Active, not recruiting
  • Pancreatic Cancer
  • multiTAA specific T cells
  • Houston, Texas
  • +2 more
Feb 7, 2022

CMV Infection, EBV Infection, Stem Cell Transplant Trial (Virus specific T cells)

Not yet recruiting
  • CMV Infection
  • +2 more
  • Virus specific T cells
  • (no location specified)
Oct 4, 2023

Antigen-specific T Cells in Antisynthetase Syndrome and

Not yet recruiting
  • Antisynthetase Syndrome
  • BAL antigen-specific Th1 cells and Th17 cells, ILC and MAIT
  • Dijon, France
  • +5 more
Aug 2, 2023

Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8 Trial in Seattle (Autologous Mesothelin-specific

Recruiting
  • Metastatic Pancreatic Ductal Adenocarcinoma
  • Stage IV Pancreatic Cancer AJCC v8
  • Autologous Mesothelin-specific TCR-T Cells
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 31, 2023

High Grade B-Cell Non-Hodgkin's Lymphoma, Intermediate Grade B-Cell Non-Hodgkin's Lymphoma, Recurrent B-Cell Non-Hodgkin

Not yet recruiting
  • High Grade B-Cell Non-Hodgkin's Lymphoma
  • +3 more
  • Anti-CD19-CAR CMV-specific T-lymphocytes
  • +9 more
  • Duarte, California
    City of Hope Medical Center
Apr 5, 2023

Leukemia, Acute Lymphoblastic Leukemia Trial in New York (gene-modified T cells targeted)

Active, not recruiting
  • Leukemia
  • Acute Lymphoblastic Leukemia
  • gene-modified T cells targeted
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Feb 1, 2023

Cytomegalovirus Infections, Solid Organ Transplant Trial in Madison (CMV specific T-cells)

Recruiting
  • Cytomegalovirus Infections
  • Solid Organ Transplant
  • CMV specific T-cells
  • Madison, Wisconsin
    University of Wisconsin School of Medicine and Public Health
Nov 14, 2022

Prostate Carcinoma, Prostate Small Cell Neuroendocrine Carcinoma, Stage III Prostate Cancer AJCC v8 Trial in Seattle (drug,

Not yet recruiting
  • Prostate Carcinoma
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 17, 2023

Multiple Myeloma in Remission Trial in Shenzhen, Haikou (MM-specific universal CAR T cells)

Recruiting
  • Multiple Myeloma in Remission
  • MM-specific universal CAR T cells
  • Shenzhen, Guangdong, China
  • +1 more
Aug 23, 2023

Liver Cell Carcinoma Trial in Houston (CATCH T cells, Cytoxan, Fludara)

Recruiting
  • Liver Cell Carcinoma
  • +7 more
  • CATCH T cells
  • +2 more
  • Houston, Texas
    Houston Methodist Hospital
Dec 19, 2022

Prostate Cancer Trial in New York (engineered autologous T cells, cyclophosphamide)

Active, not recruiting
  • Prostate Cancer
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Nov 28, 2022

Chronic Hepatitis B Trial in Beijing (TCR-T)

Active, not recruiting
  • Chronic Hepatitis B
  • TCR-T
  • Beijing, China
    The Fifth Medical Center of PLA General Hospital
Jun 13, 2023

Metastatic Colorectal Adenocarcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma Trial in

Not yet recruiting
  • Metastatic Colorectal Adenocarcinoma
  • +5 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Sep 12, 2023

B Cell Malignancies Trial in Beijing, Shenzhen, Haikou (Universal CD19-specific CAR gene-engineered T cells)

Recruiting
  • B Cell Malignancies
  • Universal CD19-specific CAR gene-engineered T cells
  • Beijing, Beijing, China
  • +2 more
Aug 8, 2023

Neuroblastoma Trial in Houston (GINAKIT Cells, Cyclophosphamide, Fludarabine)

Active, not recruiting
  • Neuroblastoma
  • GINAKIT Cells
  • +2 more
  • Houston, Texas
    Texas Children's Hospital
Jan 18, 2023

Progressive Multifocal Leukoencephalopathy Trial run by the National Institute of Neurological Disorders and Stroke (NINDS)

Completed
  • Progressive Multifocal Leukoencephalopathy
  • PyVST
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 24, 2023

Multiple Myeloma Trial in New York (drug, biological, procedure)

Active, not recruiting
  • Multiple Myeloma
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jan 3, 2023

Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory Trial in Memphis (drug, device, biological)

Active, not recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • Acute Lymphoblastic Leukemia, Refractory
  • Memphis, Tennessee
    St. Jude Children's Research Hospital
Jan 3, 2023

B-Cell Non-Hodgkin Lymphoma, DLBCL, Mantle Cell Lymphoma Trial in Duarte (Anti-CD19-CAR CMV-specific T-lymphocytes, Autologous

Not yet recruiting
  • B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Anti-CD19-CAR CMV-specific T-lymphocytes
  • +3 more
  • Duarte, California
    City of Hope Medical Center
Jun 28, 2022

Cancer Disease Trial in Shenzhen (bi-4SCAR PSMA/CD70 T cells)

Recruiting
  • Cancer Disease
  • bi-4SCAR PSMA/CD70 T cells
  • Shenzhen, Guangdong, China
    Shenzhen Geno-immune Medical Institute
Jun 25, 2022

Hepatocellular Carcinoma Trial in Singapore (mRNA HBV/TCR T-cells)

Recruiting
  • Hepatocellular Carcinoma
  • mRNA HBV/TCR T-cells
  • Singapore, Singapore
    Singapore General Hospital
Jun 27, 2022

Cancer Disease Trial in Shenzhen (bi-4SCAR GD2/CD70 T cells)

Recruiting
  • Cancer Disease
  • bi-4SCAR GD2/CD70 T cells
  • Shenzhen, Guangdong, China
    Shenzhen Geno-immune Medical Institute
Jun 25, 2022

Malignant Disease Trial in Shenzhen (bi-4SCAR GD2/CD56 T cells)

Recruiting
  • Malignant Disease
  • bi-4SCAR GD2/CD56 T cells
  • Shenzhen, Guangdong, China
    Shenzhen Geno-immune Medical Institute
Jun 25, 2022